CN Mobile Logo


Leukemia & Lymphoma

Leukemia & Lymphoma

A 5-year analysis of the DASISION trial showed that dasatinib continued to offer better responses than imatinib in patients with chronic myeloid leukemia.

A phase II study of the BCL2 inhibitor venetoclax has shown that a large majority of patients with relapsed or refractory chronic lymphocytic leukemia responded to treatment with the drug.

The early 21st century has brought with it significant improvements in survival from most common hematologic malignancies for patients aged 65 years or older, but these increases still lag behind those of 50- to 59-year-olds.

Some patients with mantle cell lymphoma may safely defer treatment for their disease, and, in fact, deferral of therapy was an independent predictor of overall survival.

Chronic myeloid leukemia patients had a significantly increased prevalence of prior malignancies and autoimmune disorders compared with the general population.

The addition of pegylated interferon-ɑ2b to dasatinib yielded promising results in a small trial of newly diagnosed chronic myeloid leukemia patients.

Blood transfusions play a key role in managing complications of acute promyelocytic leukemia (APL), involving unique blood product strategies.


Subscribe to Leukemia & Lymphoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.